VERTEX PHARMACEUTICALS INC / MA (VRTX) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0000875320 · SEC filings checked Oct 16, 2026

    Next report
    Nov 2, 2026
    Estimated from reporting history (91-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $508.75
    Polygon.io daily close, Oct 15, 2026. End of day, not live.
    Trailing diluted EPS
    $17.17
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 29.6

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 3, 2026$3.33B$1.10B$4.31Filing
    Mar 31, 2026May 4, 2026$2.99B$1.03B$4.02Filing
    Dec 31, 2025Feb 12, 2026$3.19B$1.19B$4.64Filing
    Sep 30, 2025Nov 3, 2025$3.08B$1.08B$4.20Filing
    Jun 30, 2025Aug 4, 2025$2.96B$1.03B$3.99Filing
    Mar 31, 2025May 5, 2025$2.77B$646.3M$2.49Filing
    Dec 31, 2024Feb 10, 2025$2.91B$913.0M$3.62Filing
    Sep 30, 2024Nov 4, 2024$2.77B$1.05B$4.01Filing

    What would VERTEX PHARMACEUTICALS INC / MA have to report for its valuation to change?

    At $508.75, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 20.4% a year, to $43.49. On that path the next quarter needs diluted EPS near $5.06, against $4.20 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year20.4%20.4%
    EPS needed in final year$43.49$43.49

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. VRTX goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.